ClinicalTrials.Veeva

Menu
C

Chicago Research Center, Inc. | Chicago, IL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aticaprant
JNJ-42847922
Azetukalner
AD109
Armodafinil
AD504
NRX-1074
Vilazodone
Pregabalin
Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 44 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

The study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compar...

Not yet enrolling
Hypertension
Elevated Blood Pressure
Device: Zona Plus Device
Other: Relaxing Music App

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Placebo
Drug: Azetukalner

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective sero...

Active, not recruiting
Anhedonia
Depressive Disorder, Major
Other: Placebo
Drug: Aticaprant

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only
Major Depressive Disorder
Drug: Azetukalner

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: AD109
Drug: Placebo

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Apnimed logo
Allergan logo
Boehringer Ingelheim logo
C
C
Madrigal Pharmaceuticals logo
X
Astellas logo
Avalo Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems